4- [F-18] fluoropaclitaxel

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug Name4- [F-18] fluoropaclitaxel
Drug Alias Name18F-fluoropaclitaxelFPACF-18 Paclitaxel
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsKidney NeoplasmsLung NeoplasmsAdrenal Gland Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVirginia Commonwealth University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteVirginia Commonwealth University
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsLung NeoplasmsAdrenal Gland Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A